山東新華製藥股份:2023年年報.pdf
1、目錄 CONTENTS1二零二三年年報山東新華製藥股份有限公司2公司基本情況簡介Company Information5會計數據和業務數據摘要Summary of Financial and Operating Results9股本變動及股東情況Changes in Share Capital Structure and Information on Shareholders16董事、監事、高級管理人員和員工情況Directors,Supervisors,Senior Officers and Staff30公司管治及內部控制報告Corporate Governance and Interna
2、l Control Report59股東大會簡介Summarised Report of the General Meetings61董事長報告Chairmans Statement67經營管理研討與分析Management Discussion and Analysis90董事會報告Report of the Board of Directors137環境和社會責任Environmental and Social Responsibility148監事會報告Report of the Supervisory Committee150重要事項Important Issues163財務報告Fin
3、ancial Report420備查文件Documents Available for Inspection重要提示山東新華製藥股份有限公司(本公司 或新華製藥,連同其附屬公司統稱為 集團)董事會、監事會及董事、監事、高級管理人員保證本報告所載資料不存在任何虛假記載、誤導性陳述或者重大遺漏,並對其內容的真實性、準確性和完整性承擔個別及連帶責任。董事長賀同慶先生、財務負責人侯寧先生、財務資產部經理何曉洪先生聲明:保證本年度報告中財務報告真實、完整。本報告分別以中文及英文刊載。如中英文有任何差異,概以中文為準。Important:The board of directors(“Board of D
4、irectors”)and the supervisory committee(“Supervisory Committee”)and each of the directors(“Directors”),the supervisors(“Supervisors”)and the senior management(collectively,the“Senior Officers”)of Shandong Xinhua Pharmaceutical Company Limited(the“Company”and together with its subsidiaries(the“Group”
5、)hereby confirm that there are no false representations,misleading statements or material omissions contained in this report,and they,severally and jointly,accept full responsibility for the truthfulness,accuracy and completeness of the contents of this report.The chairman(Mr.He Tongqing),financial
6、controller(Mr.Hou Ning)and the chief of the finance department(Mr.He Xiaohong)of the Company hereby declare that the financial report of the Company for 2023 is true and complete.This report has been prepared in both Chinese and English.In the event of any discrepancy between the two versions,the Ch





点击查看更多